Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology

Submitted by admin on June 1, 2023 - 6:43pm

Source:

BioSpace

News Tags:

Headline:

snippet:

Exclusive license agreement includes rights to develop and commercialize Cedilla’s CyclinE1/CDK2 inhibitors
Assets are currently in pre-clinical development with potential to serve patients with high unmet need in underserved indications
Collaboration further strengthens Bayer’s early pipeline in precision oncology

Search form